Polycythemia Vera
Conditions
Keywords
Polycythemia Vera, GIVINOSTAT, ITF2357
Brief summary
The primary objective of the study was to evaluate the efficacy of Givinostat in combination with hydroxyurea in patients with JAK2V617F-positive Polycythemia Vera (PV) non-responders to the maximum tolerated dose of hydroxyurea monotherapy. The secondary objectives of this study were: * To evaluate the safety and tolerability of Givinostat in combination with hydroxyurea in patients with JAK2V617Fpositive PV non-responders to the maximum tolerated dose of hydroxyurea monotherapy; * To explore the impact in terms of efficacy and tolerability of Givinostat 50 mg dose escalation in patients not achieving at least a partial response at the time when the primary endpoint was assessed (week 12); * To evaluate the molecular response (JAK2 mutated allele burden) by quantitative Real Time-Polymerase Chain Reaction (RT-PCR); * To evaluate the reduction of the fraction of JAK2V617F positive clonogenic progenitors.
Detailed description
This is a multicentre, randomized, open-label, phase II study testing GIVINOSTAT (ITF2357) in combination with hydroxyurea in a population of patients with JAK2V617F positive Polycythemia Vera non-responders to the maximum tolerated dose of hydroxyurea monotherapy for at least 3 months. Recruited patients will be randomly assigned to one of the following treatment groups: * group A: 50 mg o.d. of oral GIVINOSTAT (ITF2357) in combination with the maximum tolerated dose of hydroxyurea monotherapy already in use before admission to the study; * group B: 50 mg b.i.d. of oral GIVINOSTAT (ITF2357) in combination with the maximum tolerated dose of hydroxyurea monotherapy already in use before admission to the study. The two groups will be balanced for number and for Centre in order to provide valuable information on both treatment regimens. In both groups assigned doses shall remain stable until week 12, which is when the primary endpoint is assessed, unless specific tolerability issues arise which impose dose reduction. After the primary endpoint assessment at week 12, one of the following treatment schedules will be chosen case by case on the basis of the achieved clinical response and continued for up to 12 further weeks: * Partial or Complete Response at week 12: * group A: continue 50 mg o.d.; * group B: continue 50 mg b.i.d.; * No Response at week 12: * group A: increase to 50 mg b.i.d.; * group B: increase to 50 mg t.i.d.. At any time during study course, if toxicity is observed, GIVINOSTAT (ITF2357) treatment will be discontinued until recovery and then restarted at a reduced dose level. The drug will be definitively withdrawn in case of reappearance of toxicity even at a reduced daily dose. Overall, the treatment will last up to a maximum of 24 cumulative weeks of drug administration. The study will recruit subjects of both genders with an established diagnosis of JAK2V617F positive Polycythemia Vera according to the revised WHO criteria, in need of cytoreductive therapy, non-responders to the maximum tolerated dose of hydroxyurea monotherapy for at least 3 months.
Interventions
DRUGGIVINOSTAT (ITF2357) 50 mg o.d. + MTD Hydroxyurea
50 mg o.d. of GIVINOSTAT + MTD of HU monotherapy
DRUGGIVINOSTAT (ITF2357) 50 mg b.i.d. + MTD Hydroxyurea
50 mg b.i.d. of GIVINOSTAT + MTD HU monotherapy
Sponsors
Italfarmaco
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 80 Years
Healthy volunteers
No
Inclusion criteria
* Written Informed Consent. * Age ≥18 years. * Confirmed diagnosis of Polycythemia Vera according to the revised World Health Organization (WHO) criteria. * JAK2V617F positivity. * Non-response to the maximum tolerated dose of hydroxyurea monotherapy for at least 3 months. * ECOG (Eastern Cooperative Oncology Group) performance status \<3. * Use of an effective means of contraception for women of childbearing potential and men with partners of childbearing potential. * Willingness and capability to comply with the requirements of the study.
Exclusion criteria
* Active bacterial or mycotic infection requiring antimicrobial treatment. * Pregnancy or lactation. * A marked baseline prolongation of QT/QTc (corrected) interval (e.g. repeated demonstration of a QTc interval \> 450 ms, according to Bazett's correction formula). * Use of concomitant medications that prolong the QT/QTc interval. * Clinically significant cardiovascular disease including: * Uncontrolled hypertension, myocardial infarction, unstable angin, within 6 months from study start; * New York Heart Association (NYHA) Grade II or greater congestive heart failure; * History of any cardiac arrhythmia requiring medication (irrespective of its severity); * A history of additional risk factors for torsade de pointes (TdP) (e.g., heart failure, hypokalemia, family history of Long QT Syndrome). * Positive blood test for HIV (Human Immunodeficiency Virus) * Active HBV (Hepatitis B Virus) and/or HCV (Hepatitis C Virus) infection. * Platelets count \<100x109/L within 14 days before enrolment. * Absolute neutrophil count \<1.2x109/L within 14 days before enrolment. * Serum creatinine \>2xULN (upper limit of normal). * Total serum bilirubin \>1.5xULN. * Serum aspartate aminotransferase (AST) / alanine aminotransferase (ALT) \> 3xULN. * History of other diseases, metabolic dysfunctions, physical examination findings, or clinical laboratory findings giving reasonable suspicion of a disease or condition that contraindicates use of an investigational drug or that might affect interpretation of the results of the study or render the subject at high risk from treatment complications. * Interferon alpha within 14 days before enrolment. * Anagrelide within 7 days before enrolment. * Any other investigational drug within 28 days before enrolment.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Percentage of Patients With Overall Haematological Response at Week 12. | At week 12 of treatment | The percentage of patients with overall (complete or partial) response at week 12 were assessed. · Complete response: 1. HCT (Hematocrit) \< 45% without phlebotomy, and 2. platelets ≤ 400 x109/L, and 3. WBC (white blood cell) ≤ 10 x 109/L, and 4. no splenomegaly, and 5. no disease related systemic symptoms (microvascular disturbances, pruritus, headache); · Partial response: 1. HCT \< 45% without phlebotomy, or 2. fulfilment of at least 3 of the other above mentioned criteria; · No response: any response that did not satisfy the criteria set for partial response. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Percentage of Patients With Overall Haematological Response at Week 24 by Dose Escalation After Week 12. | At week 24 of treatment | Haematological response after a 50 mg increase of the initial Givinostat dose in non-responder patients at the time when the primary endpoint was assessed (week 12). * Complete response: 1. HCT\< 45% without phlebotomy, and 2. platelets ≤ 400 x109/L, and 3. WBC ≤ 10 x 109/L, and 4. no splenomegaly, and 5. no disease related systemic symptoms (microvascular disturbances, pruritus, headache); * Partial response: 1. HCT \< 45% without phlebotomy, or 2. fulfilment of at least 3 of the other above mentioned criteria; * No response: any response that did not satisfy the criteria set for partial response. |
| Change From Baseline of the JAK2V617F Allele Burden by Quantitative RT-PCR | At weeks 12, 24, at drop out visit and at End of Study (EOS). EOS stays for 7 days after last drug intake if patient is withdrawn from the study before week 24. | To determine JAK2V617F mutational status, a quantitative RT-PCR (Real Time-Polymerase Chain Reaction) is executed on peripheral blood granulocyte and haematopoietic colonies (with and without hepatocyte growth factors - HGFs). |
| Percentage of Patients With a Reduction of the Fraction of JAK2V617F Positive Clonogenic Progenitor by Timepoints | Baseline, at weeks 12 and 24 | JAK2V617F genotyping and quantification were performed on gradient-separated mononuclear cells during the pre-treatment evaluations (baseline), halfway through the study (12th weeks) and at the end of the study period (24th weeks). Baseline: n=22 (50 mg od); 22 (50 mg bid) Week 12: n=20 (50 mg od); 19 (50 mg bid) Week 24: n=18 (50 mg od); 18 (50 mg bid) |
Countries
Italy
Participant flow
Participants by arm
| Arm | Count |
|---|---|
| GIVINOSTAT + MTD Hydroxyurea_1 50 mg o.d. of GIVINOSTAT + MTD of HU monotherapy
GIVINOSTAT (ITF2357) 50 mg o.d. + MTD Hydroxyurea: 50 mg o.d. of GIVINOSTAT + MTD of HU monotherapy | 23 |
| GIVINOSTAT + MTD Hydroxyurea_2 50 mg b.i.d. of GIVINOSTAT + MTD of HU monotherapy
GIVINOSTAT (ITF2357) 50 mg b.i.d. + MTD Hydroxyurea: 50 mg b.i.d. of GIVINOSTAT + MTD HU monotherapy | 22 |
| Total | 45 |
Withdrawals & dropouts
| Period | Reason | FG000 | FG001 |
|---|---|---|---|
| Overall Study | Protocol Violation | 1 | 0 |
Baseline characteristics
| Characteristic | GIVINOSTAT + MTD Hydroxyurea_1 | GIVINOSTAT + MTD Hydroxyurea_2 | Total |
|---|---|---|---|
| Age, Categorical <=18 years | 0 Participants | 0 Participants | 0 Participants |
| Age, Categorical >=65 years | 13 Participants | 11 Participants | 24 Participants |
| Age, Categorical Between 18 and 65 years | 10 Participants | 11 Participants | 21 Participants |
| Region of Enrollment Italy | 23 participants | 22 participants | 45 participants |
| Sex: Female, Male Female | 9 Participants | 7 Participants | 16 Participants |
| Sex: Female, Male Male | 14 Participants | 15 Participants | 29 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk |
|---|---|---|
| deaths Total, all-cause mortality | 0 / 22 | 0 / 22 |
| other Total, other adverse events | 21 / 22 | 21 / 22 |
| serious Total, serious adverse events | 2 / 22 | 1 / 22 |
Outcome results
Primary
Percentage of Patients With Overall Haematological Response at Week 12.
The percentage of patients with overall (complete or partial) response at week 12 were assessed. · Complete response: 1. HCT (Hematocrit) \< 45% without phlebotomy, and 2. platelets ≤ 400 x109/L, and 3. WBC (white blood cell) ≤ 10 x 109/L, and 4. no splenomegaly, and 5. no disease related systemic symptoms (microvascular disturbances, pruritus, headache); · Partial response: 1. HCT \< 45% without phlebotomy, or 2. fulfilment of at least 3 of the other above mentioned criteria; · No response: any response that did not satisfy the criteria set for partial response.
Time frame: At week 12 of treatment
Population: Safety/ITT population: included all randomized subjects who received at least one dose of study medication.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| GIVINOSTAT + MTD Hydroxyurea_1 | Percentage of Patients With Overall Haematological Response at Week 12. | Responder | 54.5 percentage of particpants |
| GIVINOSTAT + MTD Hydroxyurea_1 | Percentage of Patients With Overall Haematological Response at Week 12. | Non responder | 45.5 percentage of particpants |
| GIVINOSTAT + MTD Hydroxyurea_2 | Percentage of Patients With Overall Haematological Response at Week 12. | Responder | 50.0 percentage of particpants |
| GIVINOSTAT + MTD Hydroxyurea_2 | Percentage of Patients With Overall Haematological Response at Week 12. | Non responder | 50.0 percentage of particpants |
Secondary
Change From Baseline of the JAK2V617F Allele Burden by Quantitative RT-PCR
To determine JAK2V617F mutational status, a quantitative RT-PCR (Real Time-Polymerase Chain Reaction) is executed on peripheral blood granulocyte and haematopoietic colonies (with and without hepatocyte growth factors - HGFs).
Time frame: At weeks 12, 24, at drop out visit and at End of Study (EOS). EOS stays for 7 days after last drug intake if patient is withdrawn from the study before week 24.
Population: Safety/Intention-to-treat (ITT) population, which included all randomized subjects who received at least one dose of study medication.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| GIVINOSTAT + MTD Hydroxyurea_1 | Change From Baseline of the JAK2V617F Allele Burden by Quantitative RT-PCR | Week 12 | -2.6 percent change | Standard Deviation 8.2 |
| GIVINOSTAT + MTD Hydroxyurea_1 | Change From Baseline of the JAK2V617F Allele Burden by Quantitative RT-PCR | Drop-out | -4.0 percent change | Standard Deviation 0 |
| GIVINOSTAT + MTD Hydroxyurea_1 | Change From Baseline of the JAK2V617F Allele Burden by Quantitative RT-PCR | Week 24 | -3.8 percent change | Standard Deviation 11.5 |
| GIVINOSTAT + MTD Hydroxyurea_1 | Change From Baseline of the JAK2V617F Allele Burden by Quantitative RT-PCR | EOS | -3.8 percent change | Standard Deviation 11.1 |
| GIVINOSTAT + MTD Hydroxyurea_2 | Change From Baseline of the JAK2V617F Allele Burden by Quantitative RT-PCR | EOS | 3.0 percent change | Standard Deviation 8.6 |
| GIVINOSTAT + MTD Hydroxyurea_2 | Change From Baseline of the JAK2V617F Allele Burden by Quantitative RT-PCR | Week 12 | 0.00 percent change | Standard Deviation 6 |
| GIVINOSTAT + MTD Hydroxyurea_2 | Change From Baseline of the JAK2V617F Allele Burden by Quantitative RT-PCR | Week 24 | 4.6 percent change | Standard Deviation 5.7 |
| GIVINOSTAT + MTD Hydroxyurea_2 | Change From Baseline of the JAK2V617F Allele Burden by Quantitative RT-PCR | Drop-out | -9.5 percent change | Standard Deviation 20.5 |
Secondary
Percentage of Patients With a Reduction of the Fraction of JAK2V617F Positive Clonogenic Progenitor by Timepoints
JAK2V617F genotyping and quantification were performed on gradient-separated mononuclear cells during the pre-treatment evaluations (baseline), halfway through the study (12th weeks) and at the end of the study period (24th weeks). Baseline: n=22 (50 mg od); 22 (50 mg bid) Week 12: n=20 (50 mg od); 19 (50 mg bid) Week 24: n=18 (50 mg od); 18 (50 mg bid)
Time frame: Baseline, at weeks 12 and 24
Population: Safety/Intention-to-treat (ITT) population, which included all randomized subjects who received at least one dose of study medication.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| GIVINOSTAT + MTD Hydroxyurea_1 | Percentage of Patients With a Reduction of the Fraction of JAK2V617F Positive Clonogenic Progenitor by Timepoints | Baseline - homozygous | 72.7 percentage of participants |
| GIVINOSTAT + MTD Hydroxyurea_1 | Percentage of Patients With a Reduction of the Fraction of JAK2V617F Positive Clonogenic Progenitor by Timepoints | week 12 - not done | 5.0 percentage of participants |
| GIVINOSTAT + MTD Hydroxyurea_1 | Percentage of Patients With a Reduction of the Fraction of JAK2V617F Positive Clonogenic Progenitor by Timepoints | week 12 - heterozygous | 25.0 percentage of participants |
| GIVINOSTAT + MTD Hydroxyurea_1 | Percentage of Patients With a Reduction of the Fraction of JAK2V617F Positive Clonogenic Progenitor by Timepoints | week 24 - heterozygous | 22.2 percentage of participants |
| GIVINOSTAT + MTD Hydroxyurea_1 | Percentage of Patients With a Reduction of the Fraction of JAK2V617F Positive Clonogenic Progenitor by Timepoints | Baseline - not done | 0 percentage of participants |
| GIVINOSTAT + MTD Hydroxyurea_1 | Percentage of Patients With a Reduction of the Fraction of JAK2V617F Positive Clonogenic Progenitor by Timepoints | week 24 - homozygous | 72.2 percentage of participants |
| GIVINOSTAT + MTD Hydroxyurea_1 | Percentage of Patients With a Reduction of the Fraction of JAK2V617F Positive Clonogenic Progenitor by Timepoints | week 12 - homozygous | 70.0 percentage of participants |
| GIVINOSTAT + MTD Hydroxyurea_1 | Percentage of Patients With a Reduction of the Fraction of JAK2V617F Positive Clonogenic Progenitor by Timepoints | week 24 - not done | 5.6 percentage of participants |
| GIVINOSTAT + MTD Hydroxyurea_1 | Percentage of Patients With a Reduction of the Fraction of JAK2V617F Positive Clonogenic Progenitor by Timepoints | Baseline - heterozygous | 27.3 percentage of participants |
| GIVINOSTAT + MTD Hydroxyurea_2 | Percentage of Patients With a Reduction of the Fraction of JAK2V617F Positive Clonogenic Progenitor by Timepoints | week 24 - not done | 11.1 percentage of participants |
| GIVINOSTAT + MTD Hydroxyurea_2 | Percentage of Patients With a Reduction of the Fraction of JAK2V617F Positive Clonogenic Progenitor by Timepoints | Baseline - heterozygous | 22.7 percentage of participants |
| GIVINOSTAT + MTD Hydroxyurea_2 | Percentage of Patients With a Reduction of the Fraction of JAK2V617F Positive Clonogenic Progenitor by Timepoints | Baseline - homozygous | 72.7 percentage of participants |
| GIVINOSTAT + MTD Hydroxyurea_2 | Percentage of Patients With a Reduction of the Fraction of JAK2V617F Positive Clonogenic Progenitor by Timepoints | Baseline - not done | 4.5 percentage of participants |
| GIVINOSTAT + MTD Hydroxyurea_2 | Percentage of Patients With a Reduction of the Fraction of JAK2V617F Positive Clonogenic Progenitor by Timepoints | week 12 - heterozygous | 31.6 percentage of participants |
| GIVINOSTAT + MTD Hydroxyurea_2 | Percentage of Patients With a Reduction of the Fraction of JAK2V617F Positive Clonogenic Progenitor by Timepoints | week 12 - homozygous | 63.2 percentage of participants |
| GIVINOSTAT + MTD Hydroxyurea_2 | Percentage of Patients With a Reduction of the Fraction of JAK2V617F Positive Clonogenic Progenitor by Timepoints | week 12 - not done | 5.3 percentage of participants |
| GIVINOSTAT + MTD Hydroxyurea_2 | Percentage of Patients With a Reduction of the Fraction of JAK2V617F Positive Clonogenic Progenitor by Timepoints | week 24 - heterozygous | 11.1 percentage of participants |
| GIVINOSTAT + MTD Hydroxyurea_2 | Percentage of Patients With a Reduction of the Fraction of JAK2V617F Positive Clonogenic Progenitor by Timepoints | week 24 - homozygous | 77.8 percentage of participants |
Secondary
Percentage of Patients With Overall Haematological Response at Week 24 by Dose Escalation After Week 12.
Haematological response after a 50 mg increase of the initial Givinostat dose in non-responder patients at the time when the primary endpoint was assessed (week 12). * Complete response: 1. HCT\< 45% without phlebotomy, and 2. platelets ≤ 400 x109/L, and 3. WBC ≤ 10 x 109/L, and 4. no splenomegaly, and 5. no disease related systemic symptoms (microvascular disturbances, pruritus, headache); * Partial response: 1. HCT \< 45% without phlebotomy, or 2. fulfilment of at least 3 of the other above mentioned criteria; * No response: any response that did not satisfy the criteria set for partial response.
Time frame: At week 24 of treatment
Population: Safety/Intention to treat (ITT) population included all randomized subjects who received at least one dose of study medication.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| GIVINOSTAT + MTD Hydroxyurea_1 | Percentage of Patients With Overall Haematological Response at Week 24 by Dose Escalation After Week 12. | Responder | 63.6 percentage of participants |
| GIVINOSTAT + MTD Hydroxyurea_1 | Percentage of Patients With Overall Haematological Response at Week 24 by Dose Escalation After Week 12. | Non responder | 36.4 percentage of participants |
| GIVINOSTAT + MTD Hydroxyurea_2 | Percentage of Patients With Overall Haematological Response at Week 24 by Dose Escalation After Week 12. | Responder | 40.9 percentage of participants |
| GIVINOSTAT + MTD Hydroxyurea_2 | Percentage of Patients With Overall Haematological Response at Week 24 by Dose Escalation After Week 12. | Non responder | 59.1 percentage of participants |